Sanofi: Carcinoma, Hepatocellular trials
The registry lists 10 Carcinoma, Hepatocellular studies with Sanofi as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 4Phase 2 7Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)CompletedNCT05104567Phase 2Results posted
- A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesTerminatedNCT03829501Phase 1/2Results posted
- Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)CompletedNCT00508001Phase 2Results posted
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Phase 1
- Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma PatientsWithdrawnNCT01245582Phase 3
- Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver CarcinomaTerminatedNCT00791544Phase 1/2
- Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT00559455Phase 2
- Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma PatientsCompletedNCT00471965Phase 3
- Oxaliplatin in Unresectable Hepatocellular CarcinomaCompletedNCT00280618Phase 2
- A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical CareTerminatedNCT00081900Phase 1/2